KR100854851B1 - 당뇨병 치료에 유용한 ＦＢＰａｓｅ 억제제와 항당뇨제의조합물 - Google Patents

당뇨병 치료에 유용한 ＦＢＰａｓｅ 억제제와 항당뇨제의조합물 Download PDF

Info

Publication number
KR100854851B1
KR100854851B1 KR1020037000126A KR20037000126A KR100854851B1 KR 100854851 B1 KR100854851 B1 KR 100854851B1 KR 1020037000126 A KR1020037000126 A KR 1020037000126A KR 20037000126 A KR20037000126 A KR 20037000126A KR 100854851 B1 KR100854851 B1 KR 100854851B1
Authority
KR
South Korea
Prior art keywords
alkyl
aryl
substituted
group
heteroaryl
Prior art date
Application number
KR1020037000126A
Other languages
English (en)
Korean (ko)
Other versions
KR20030031952A (ko
Inventor
파울 데. 반포엘예
마크 디. 에리온
도시히꼬 후지와라
Original Assignee
메타베이시스 테라퓨틱스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메타베이시스 테라퓨틱스, 인크. filed Critical 메타베이시스 테라퓨틱스, 인크.
Publication of KR20030031952A publication Critical patent/KR20030031952A/ko
Application granted granted Critical
Publication of KR100854851B1 publication Critical patent/KR100854851B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020037000126A 2000-07-06 2001-07-05 당뇨병 치료에 유용한 ＦＢＰａｓｅ 억제제와 항당뇨제의조합물 KR100854851B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21653100P 2000-07-06 2000-07-06
US60/216,531 2000-07-06
PCT/US2001/021557 WO2002003978A2 (en) 2000-07-06 2001-07-05 A COMBINATION OF FBPase INHIBITORS AND ANTIDIABETIC AGENTS USEFUL FOR THE TREATMENT OF DIABETES

Publications (2)

Publication Number Publication Date
KR20030031952A KR20030031952A (ko) 2003-04-23
KR100854851B1 true KR100854851B1 (ko) 2008-08-27

Family

ID=22807416

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020037000126A KR100854851B1 (ko) 2000-07-06 2001-07-05 당뇨병 치료에 유용한 ＦＢＰａｓｅ 억제제와 항당뇨제의조합물

Country Status (18)

Country Link
EP (1) EP1372660A2 (ru)
JP (1) JP2004508297A (ru)
KR (1) KR100854851B1 (ru)
CN (2) CN100396283C (ru)
AU (2) AU2001273271B2 (ru)
BR (1) BR0112212A (ru)
CA (1) CA2412142A1 (ru)
CZ (1) CZ20035A3 (ru)
HU (1) HUP0301830A3 (ru)
IL (2) IL153513A0 (ru)
MX (1) MXPA02012713A (ru)
NO (1) NO20030034L (ru)
NZ (1) NZ523227A (ru)
PL (1) PL365779A1 (ru)
RU (1) RU2328308C2 (ru)
SK (1) SK62003A3 (ru)
WO (1) WO2002003978A2 (ru)
ZA (1) ZA200300044B (ru)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6284748B1 (en) 1997-03-07 2001-09-04 Metabasis Therapeutics, Inc. Purine inhibitors of fructose 1,6-bisphosphatase
CA2343027A1 (en) 1998-09-09 2000-03-16 Metabasis Therapeutics, Inc. Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase
ATE350385T1 (de) 2000-03-08 2007-01-15 Metabasis Therapeutics Inc Neue aryl fructose-1,6-bisphosphatase inhibitoren
DE60230818D1 (de) 2001-09-24 2009-02-26 Imp Innovations Ltd Pyy3-36 zur zur reduzierung oder vorbeugung von fettleibigkeit
WO2003057235A2 (en) 2002-01-10 2003-07-17 Imperial College Innovations Ltd Modification of feeding behavior
GB0300571D0 (en) 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
SI3002283T1 (en) 2003-12-26 2018-06-29 Kyowa Hakko Kirin Co., Ltd. Thiazole derivatives
CN101005847A (zh) * 2004-08-18 2007-07-25 症变治疗公司 果糖1,6－双磷酸酶的新颖噻唑类抑制剂
EP1857118A1 (en) * 2004-12-13 2007-11-21 Daiichi Sankyo Company, Limited Medicinal composition for treating diabetes
TW200738245A (en) * 2005-08-22 2007-10-16 Sankyo Co Pharmaceutical composition containing FBPase inhibitor
WO2007129522A1 (ja) * 2006-04-10 2007-11-15 Daiichi Sankyo Company, Limited 乾式製造法製剤
US20100076037A1 (en) 2006-11-02 2010-03-25 Chiang Lillian W Methods of Treating Neuropathic Pain with Agonists of PPAR-gamma
TWI428346B (zh) 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
CN107312039B (zh) 2012-08-30 2019-06-25 江苏豪森药业集团有限公司 一种替诺福韦前药的制备方法
UY35065A (es) * 2012-10-08 2014-05-30 Lg Life Sciences Ltd Fármaco combinado que comprende gemigliptina y metformina y método para su preparación
CN104788350A (zh) * 2014-01-22 2015-07-22 天津大学 一种通过快速冷却结晶法获得甲糖宁药用优势晶型的方法
CN106831437B (zh) * 2016-02-03 2019-06-21 华中师范大学 含硝基乙烯基的酯类化合物及其制备方法和应用
CN114907285B (zh) * 2021-02-10 2023-09-22 华中师范大学 酰化糖精类化合物及其制备方法和应用、降血糖药物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999047549A1 (en) * 1998-03-16 1999-09-23 Ontogen Corporation PIPERAZINES AS INHIBITORS OF FRUCTOSE-1,6-BISPHOSPHATASE (FBPase)
WO2000014095A1 (en) * 1998-09-09 2000-03-16 Metabasis Therapeutics, Inc. Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5086190A (en) * 1989-01-24 1990-09-05 Gensia Pharmaceuticals, Inc. Method and compounds for aica riboside delivery and for lowering blood glucose
US6284748B1 (en) * 1997-03-07 2001-09-04 Metabasis Therapeutics, Inc. Purine inhibitors of fructose 1,6-bisphosphatase
US6054587A (en) * 1997-03-07 2000-04-25 Metabasis Therapeutics, Inc. Indole and azaindole inhibitors of fructose-1,6-bisphosphatase
AU6691498A (en) * 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel benzimidazole inhibitors of fructose-1,6-bisphosphatase
BR9917005A (pt) * 1998-12-24 2002-04-02 Metabasis Therapeutics Inc Combinação de inibidores de fbpase e sensibilizadores de insulina para o tratamento de diabete
CA2673615C (en) * 2000-01-21 2013-07-16 Novartis Ag Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents
GB0015627D0 (en) * 2000-06-26 2000-08-16 Rademacher Group Limited Phosphoglycan messengers and their medical uses

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999047549A1 (en) * 1998-03-16 1999-09-23 Ontogen Corporation PIPERAZINES AS INHIBITORS OF FRUCTOSE-1,6-BISPHOSPHATASE (FBPase)
WO2000014095A1 (en) * 1998-09-09 2000-03-16 Metabasis Therapeutics, Inc. Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase

Also Published As

Publication number Publication date
RU2328308C2 (ru) 2008-07-10
WO2002003978A2 (en) 2002-01-17
PL365779A1 (en) 2005-01-10
AU2001273271B2 (en) 2006-01-05
WO2002003978A3 (en) 2003-10-16
HUP0301830A3 (en) 2007-10-29
IL153513A0 (en) 2003-07-06
IL153513A (en) 2014-07-31
JP2004508297A (ja) 2004-03-18
NO20030034D0 (no) 2003-01-03
BR0112212A (pt) 2003-12-30
CA2412142A1 (en) 2002-01-17
AU7327101A (en) 2002-01-21
EP1372660A2 (en) 2004-01-02
CZ20035A3 (cs) 2003-05-14
CN101301294A (zh) 2008-11-12
ZA200300044B (en) 2004-05-06
NZ523227A (en) 2005-04-29
SK62003A3 (en) 2003-09-11
MXPA02012713A (es) 2004-09-10
CN100396283C (zh) 2008-06-25
HUP0301830A2 (hu) 2003-11-28
KR20030031952A (ko) 2003-04-23
NO20030034L (no) 2003-03-05
CN1599612A (zh) 2005-03-23

Similar Documents

Publication Publication Date Title
US20090197836A1 (en) Combination of FBPase Inhibitors and Antidiabetic Agents Useful for the Treatment of Diabetes
KR100854851B1 (ko) 당뇨병 치료에 유용한 ＦＢＰａｓｅ 억제제와 항당뇨제의조합물
KR100689943B1 (ko) 당뇨병 치료용 ＦＢＰａｓｅ 억제제 및 인슐린 증감제의조합물
US20080004226A1 (en) Combination of FBPase Inhibitors and Insulin Sensitizers for the Treatment of Diabetes
AU2001273271A1 (en) A combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
KR100818845B1 (ko) 신규한 프럭토스 1,6-비스포스파타제의 헤테로방향족 억제제
AU784370B2 (en) Novel bisamidate phosphonate prodrugs
KR20020079988A (ko) 신규한 아릴 프럭토스-1,6-비스포스파타제 억제제
AU2006201410A1 (en) A combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
EP1552850A2 (en) A combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
N231 Notification of change of applicant
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20121121

Year of fee payment: 5

FPAY Annual fee payment

Payment date: 20130808

Year of fee payment: 6

FPAY Annual fee payment

Payment date: 20140806

Year of fee payment: 7

FPAY Annual fee payment

Payment date: 20150716

Year of fee payment: 8

FPAY Annual fee payment

Payment date: 20160720

Year of fee payment: 9

FPAY Annual fee payment

Payment date: 20170719

Year of fee payment: 10

FPAY Annual fee payment

Payment date: 20180718

Year of fee payment: 11